Ind-Swift Laboratories Ltd

Ind-Swift Labs. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Ind-Swift Laboratories Ltd

₹ 110 -0.05%
18 May - close price
indswiftlabs.com BSE: 532305 NSE: INDSWFTLAB
About

Incorporated in 1995, Ind-Swift Laboratories Ltd is in the business of Bulk Drugs & Pharmaceuticals[1]

Key Points

Business Overview:[1]
ISLL is a global manufacture of APIs, Intermediates and formulation (through group collaboration). It caters to the API needs of regulated markets including USFDA, EDQM, PMDA, ANVISA, EU-GMP, KFDA, NMO, ANSM, Cofepris, TGA, WHO, ROW. ISLL is present in all stages of drug substance/product including new chemical/molecular research to formulation development.
Company manufactures APIs towards Cardiovascular health, Antihistamine, Antidiabetic, Antipsychotic, Antimigraine, Parkinson’s Disease, Antineoplastic, ADHD Symptoms, Analgesics, Alcohol Abstinence and Bone Resorption Inhibitor. It also holds global leadership positions in the Macrolide Antibiotic segment.

Website BSE NSE
  • Market Cap ₹ 651 Cr.
  • Current Price ₹ 110
  • High / Low ₹ 138 / 67.0
  • Stock P/E 4.40
  • Book Value ₹ 158
  • Dividend Yield 0.00 %
  • ROCE 19.8 %
  • ROE 18.4 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Stock is trading at 0.70 times its book value
  • Company has delivered good profit growth of 43.3% CAGR over last 5 years
  • Debtor days have improved from 120 to 48.2 days.

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • The company has delivered a poor sales growth of 11.1% over past five years.
  • Company has a low return on equity of 10.3% over last 3 years.
  • Promoters have pledged 48.6% of their holding.
  • Earnings include an other income of Rs.432 Cr.
  • Company's cost of borrowing seems high

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
227 250 236 247 307 280 310 313 304 310 290 288 393
185 199 180 194 270 227 251 259 241 250 224 236 431
Operating Profit 42 51 56 52 37 53 59 54 64 60 66 52 -37
OPM % 18% 21% 24% 21% 12% 19% 19% 17% 21% 19% 23% 18% -9%
3 6 7 8 21 7 8 8 -16 6 7 7 412
Interest 24 24 24 24 23 24 24 22 22 20 21 21 -11
Depreciation 28 14 14 21 82 16 16 15 9 14 13 14 13
Profit before tax -8 19 25 16 -47 20 26 24 16 32 39 24 373
Tax % -264% 1% 3% -1% -30% 1% 2% -13% 255% 45% 18% 19% 36%
-29 19 24 16 -61 20 25 28 -25 17 32 19 239
EPS in Rs -4.94 3.18 4.14 2.71 -10.40 3.36 4.29 4.65 -4.25 2.92 5.36 3.29 40.42
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
1,134 965 660 653 716 765 757 780 891 1,039 1,207 1,281
1,063 906 571 546 610 631 630 635 709 837 978 1,027
Operating Profit 72 59 89 107 106 134 126 144 183 202 229 254
OPM % 6% 6% 13% 16% 15% 18% 17% 19% 21% 19% 19% 20%
4 -19 -31 1 15 16 120 33 23 37 7 432
Interest 140 117 117 106 88 28 92 107 100 96 92 51
Depreciation 54 66 84 85 88 87 104 90 87 131 57 53
Profit before tax -119 -142 -143 -83 -55 36 50 -20 18 13 87 582
Tax % 1% 14% 17% 29% 29% 39% 42% -7% 117% 117% 45% 28%
-118 -122 -119 -59 -39 22 29 -21 -3 -2 48 421
EPS in Rs -30.02 -29.79 -29.14 -14.33 -8.75 4.85 6.09 -3.59 -0.53 -0.36 8.06 71.24
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 3%
5 Years: 11%
3 Years: 13%
TTM: 6%
Compounded Profit Growth
10 Years: 14%
5 Years: 43%
3 Years: 266%
TTM: 141%
Stock Price CAGR
10 Years: 8%
5 Years: 27%
3 Years: 11%
1 Year: 58%
Return on Equity
10 Years: 0%
5 Years: 6%
3 Years: 10%
Last Year: 18%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 39 41 42 42 45 46 48 60 60 60 60 59
Reserves 814 684 553 476 486 507 540 581 544 541 622 872
1,240 1,355 1,413 1,457 1,242 1,083 1,148 1,031 1,005 953 862 17
280 258 236 240 364 387 188 198 210 247 280 217
Total Liabilities 2,374 2,339 2,244 2,215 2,138 2,023 1,924 1,870 1,818 1,801 1,824 1,165
1,171 1,174 1,117 1,099 1,042 934 914 843 753 630 587 8
CWIP 161 78 113 78 70 69 20 11 19 10 8 0
Investments 17 17 18 18 18 18 19 17 36 29 30 111
1,025 1,070 997 1,020 1,007 1,002 972 998 1,011 1,131 1,199 1,047
Total Assets 2,374 2,339 2,244 2,215 2,138 2,023 1,924 1,870 1,818 1,801 1,824 1,165

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
-47 0 98 79 96 73 -64 125 135 150 195 -163
-48 0 -35 -29 -31 -17 -12 -9 -10 5 -13 -104
66 0 -64 -48 -69 -62 100 -133 -124 -141 -186 699
Net Cash Flow -29 0 -1 3 -4 -6 23 -17 1 14 -4 431

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 133 168 215 208 182 194 169 186 177 160 153 48
Inventory Days 180 182 312 368 305 291 284 315 301 288 242 6
Days Payable 81 103 120 137 91 118 114 124 111 118 113 52
Cash Conversion Cycle 232 247 407 439 396 367 339 377 367 330 282 2
Working Capital Days 246 277 379 255 110 99 305 313 303 290 267 4
ROCE % 2% 0% 1% 2% 2% 4% 4% 5% 7% 7% 13%

Shareholding Pattern

Numbers in percentages

57 Recently
Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
42.00% 42.00% 42.00% 42.00% 42.00% 42.01% 42.01% 42.01% 42.01% 42.01% 42.01% 42.01%
0.05% 0.01% 0.22% 0.06% 0.00% 0.00% 0.04% 0.00% 0.08% 0.17% 0.31% 0.26%
19.50% 19.49% 19.50% 19.49% 19.49% 19.49% 19.49% 19.49% 19.49% 19.49% 18.73% 8.03%
38.46% 38.50% 38.29% 38.44% 38.50% 38.51% 38.48% 38.52% 38.44% 38.34% 38.96% 49.72%
No. of Shareholders 21,46625,22524,52825,34224,91024,22624,45623,39722,96225,40524,63322,439

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls

  • Nov 2020
    Transcript
    Notes
    PPT
  • Jul 2020
    Transcript
    Notes
    PPT